Literature DB >> 24026210

The BRAF V600K mutation is more frequent than the BRAF V600E mutation in melanoma in situ of lentigo maligna type.

Elke Stadelmeyer1, Ellen Heitzer2, Margit Resel1, Lorenzo Cerroni3, Peter Wolf4, Nadia Dandachi5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24026210     DOI： 10.1038/jid.2013.338

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  21 in total

1.  Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes.

Authors:  Julie Lang; Rona M MacKie
Journal:  J Invest Dermatol       Date:  2005-09       Impact factor: 8.551

2.  Method of mutation analysis may contribute to discrepancies in reports of (V599E)BRAF mutation frequencies in melanocytic neoplasms.

Authors:  Christopher J Miller; Mitchell Cheung; Arati Sharma; Loren Clarke; Klaus Helm; David Mauger; Gavin P Robertson
Journal:  J Invest Dermatol       Date:  2004-11       Impact factor: 8.551

3.  Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.

Authors:  Alexander M Menzies; Lauren E Haydu; Lydia Visintin; Matteo S Carlino; Julie R Howle; John F Thompson; Richard F Kefford; Richard A Scolyer; Georgina V Long
Journal:  Clin Cancer Res       Date:  2012-04-24       Impact factor: 12.531

4.  T1799A BRAF mutation is common in PUVA lentigines.

Authors:  Anita Lassacher; Miriam Worda; Steven Kaddu; Ellen Heitzer; Franz Legat; Cesare Massone; Lorenzo Cerroni; Helmut Kerl; Honnavara N Ananthaswamy; Peter Wolf
Journal:  J Invest Dermatol       Date:  2006-03-23       Impact factor: 8.551

5.  Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.

Authors:  Gerald Saldanha; Linda Potter; Philip Daforno; J Howard Pringle
Journal:  Clin Cancer Res       Date:  2006-08-01       Impact factor: 12.531

6.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Authors:  Jeffrey A Sosman; Kevin B Kim; Lynn Schuchter; Rene Gonzalez; Anna C Pavlick; Jeffrey S Weber; Grant A McArthur; Thomas E Hutson; Stergios J Moschos; Keith T Flaherty; Peter Hersey; Richard Kefford; Donald Lawrence; Igor Puzanov; Karl D Lewis; Ravi K Amaravadi; Bartosz Chmielowski; H Jeffrey Lawrence; Yu Shyr; Fei Ye; Jiang Li; Keith B Nolop; Richard J Lee; Andrew K Joe; Antoni Ribas
Journal:  N Engl J Med       Date:  2012-02-23       Impact factor: 91.245

7.  The association between MC1R genotype and BRAF mutation status in cutaneous melanoma: findings from an Australian population.

Authors:  Elke Hacker; Nicholas K Hayward; Troy Dumenil; Michael R James; David C Whiteman
Journal:  J Invest Dermatol       Date:  2010-01       Impact factor: 8.551

8.  High frequency of BRAF mutations in nevi.

Authors:  Pamela M Pollock; Ursula L Harper; Katherine S Hansen; Laura M Yudt; Mitchell Stark; Christiane M Robbins; Tracy Y Moses; Galen Hostetter; Urs Wagner; John Kakareka; Ghadi Salem; Tom Pohida; Peter Heenan; Paul Duray; Olli Kallioniemi; Nicholas K Hayward; Jeffrey M Trent; Paul S Meltzer
Journal:  Nat Genet       Date:  2002-11-25       Impact factor: 38.330

9.  Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma.

Authors:  Lars A Akslen; Hanne Puntervoll; Ingeborg M Bachmann; Oddbjørn Straume; Edda Vuhahula; Rajiv Kumar; Anders Molven
Journal:  Melanoma Res       Date:  2008-02       Impact factor: 3.599

Review 10.  Lentigo maligna and lentigo maligna melanoma.

Authors:  L M Cohen
Journal:  J Am Acad Dermatol       Date:  1995-12       Impact factor: 11.527
View more
  9 in total

Review 1.  Lentigo maligna and lentigo maligna melanoma: contemporary issues in diagnosis and management.

Authors:  Karen L Connolly; Kishwer S Nehal; Klaus J Busam
Journal:  Melanoma Manag       Date:  2015-05-18

Review 2.  Emerging strategies to treat rare and intractable subtypes of melanoma.

Authors:  Gretchen M Alicea; Vito W Rebecca
Journal:  Pigment Cell Melanoma Res       Date:  2020-04-24       Impact factor: 4.693

Review 3.  Systemic BRAF/MEK Inhibitors as a Potential Treatment Option in Metastatic Conjunctival Melanoma.

Authors:  Joel M Mor; Ludwig M Heindl
Journal:  Ocul Oncol Pathol       Date:  2016-12-08

4.  Putative genomic characteristics of BRAF V600K versus V600E cutaneous melanoma.

Authors:  Yuanyuan Li; David M Umbach; Leping Li
Journal:  Melanoma Res       Date:  2017-12       Impact factor: 3.599

Review 5.  From melanocytes to melanomas.

Authors:  A Hunter Shain; Boris C Bastian
Journal:  Nat Rev Cancer       Date:  2016-04-29       Impact factor: 60.716

6.  Histologic Features Associated With an Invasive Component in Lentigo Maligna Lesions.

Authors:  Angela Moreno; Esperanza Manrique-Silva; Amaya Virós; Celia Requena; Onofre Sanmartín; Víctor Traves; Eduardo Nagore
Journal:  JAMA Dermatol       Date:  2019-07-01       Impact factor: 10.282

7.  Targeting of the MAPK and AKT pathways in conjunctival melanoma shows potential synergy.

Authors:  Martine J Jager; Robert M Verdijk; Jinfeng Cao; Renier C Heijkants; Aart G Jochemsen; Mehmet Dogrusöz; Mark J de Lange; Pieter A van der Velden; Sjoerd H van der Burg
Journal:  Oncotarget       Date:  2016-07-22

8.  Tumor genetic heterogeneity analysis of chronic sun-damaged melanoma.

Authors:  Adriana Sanna; Katja Harbst; Iva Johansson; Gustav Christensen; Martin Lauss; Shamik Mitra; Frida Rosengren; Jari Häkkinen; Johan Vallon-Christersson; Håkan Olsson; Åsa Ingvar; Karolin Isaksson; Christian Ingvar; Kari Nielsen; Göran Jönsson
Journal:  Pigment Cell Melanoma Res       Date:  2019-12-23       Impact factor: 4.693

9.  Guanine nucleotide exchange factor H1 can be a new biomarker of melanoma.

Authors:  Jie Shi; Bingyu Guo; Yu Zhang; Qiang Hui; Peng Chang; Kai Tao
Journal:  Biologics       Date:  2016-07-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.